Factors influencing screening

In spite of what appear to be advanced screening methods for osteoporosis, the rate of screening is still very low among postmenopausal women. In a survey of Medicare claims from 2005 involving women aged 65 years and older, only 12.9% were given a diagnostic BMD exam.28,29 At this point, the reasons for this low usage rate can only be speculated on. In all likelihood, several factors are compounded to produce this phenomenon.

Confusion. Many different organizations worldwide have promulgated criteria for osteoporosis screening and the threshold at which a person is considered to have osteoporosis.30 The WHO, USPSTF, and IOF are the most prominent groups whose work permeates current literature. Although most of the recommendations set forth by these organizations are similar, variations can be found in such areas as the age at initial screening and the levels of bone density that define osteoporosis.22 When regulatory bodies disagree and each set of authors recommend something different than the last, the result is often inaction.31


Continue Reading

If health-care practitioners are unsure of the true standard of care, it is unlikely that their patients will be any more confident. Public-health education, thanks largely to the pharmaceutical industry, has improved greatly over the past 10 years with respect to raising awareness of osteoporosis. However, the television advertisements always end with a disclaimer instructing patients to “discuss this with a health-care provider.” Once practitioners have reviewed information about calcium, vitamin D, weight-bearing exercise, and estrogen supplementation, the discussion may be over. If the practitioner and the patient are both unclear about the need for BMD testing, it is doubtful that the practitioner will recommend or order the test.

Finances. Financial concerns affect provider and patient alike. For the patient, the issue is affordability or insurance coverage. For the practitioner, it is reimbursement, either from the patient or a third-party payer.32

The typical DEXA scan in 2007 cost the providing facility $137.32 Medicare and Medicaid reimbursement for this procedure at that time was $139.46.33,34 Obviously, this was not an income-generating test, but it at least provided break-even reimbursement. However, the Centers for Medicare & Medicaid Services have proposed cuts that would take the reimbursement to a low of $55 per test by the end of this year.33,34 This action will impact BMD testing from two directions: (1) Practitioners who depend solely on Medicare for revenue will stop ordering the test or bill the patient for the difference; and (2) patients will be hesitant to request the test if they have to pay out-of-pocket.

Availability. Ready access to a BMD-testing facility is not usually a problem. All medium and large population areas have multiple facilities, and two thirds of DEXA scans are performed in private community offices, making the test available in most outlying areas.35

The small, portable ultrasound densitometer that tests calcaneal bone is frequently used in community health fairs or retail health clinics. While the overall accuracy of this test is not equal to a composite DEXA scan, it at least provides a basis for decisions about further screening.7 The advantages of densitometry are its low cost, portability, and ease of use.

Patient education and awareness. Regardless of any other concerns, patient education and awareness are the most important factors in osteoporosis screening for postmenopausal women. No practitioner can be responsible for all aspects of an individual’s wellness, especially when the person is not an active participant in the process. Becoming informed and proactive about their own health is absolutely essential for women. In women’s journals, authors of health articles often discuss osteoporosis and associated risk factors. Even if a patient opts not to pursue formal screening in the form of a DEXA scan, she can at least become familiar with her risk profile and take basic steps to counteract the disease process.10

Dr. Sego is a staff clinician at the VA Hospital in Kansas City, Mo., where she practices adult medicine and women’s health. She has no relationship to disclose relating to the content of this article.


HOW TO TAKE THE POST-TEST: To obtain CME/CE credit, please click here after reading the article to take the post-test on myCME.com.


References

  1. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25-54.
  2. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-541.
  3. Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009;79:193-200.
  4. Kanis JA, Johnell O, Oden A, et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone. 2002;30:251-258.
  5. U.S. Department of Health & Human Services. Bone health and osteoporosis: a report of the Surgeon General (2004).
  6. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
  7. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
  8. Lata PF, Elliott ME. Patient assessment in the diagnosis, prevention, and treatment of osteoporosis. Nutr Clin Pract. 2007;22:261-275.
  9. Lydick E, Cook K, Turpin J, et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1998;4:37-48.
  10. Cadarette SM, Jaglal SB, Kreiger N, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 2000;162:1289-1294.
  11. National Osteoporosis Foundation. WHO Scientific Group on the assessment of osteoporosis at the primary health care level. Summary Meeting Report, Brussels, Belgium, 2004.
  12. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276.
  13. van Meurs JB, Trikalinos TA, Ralston SH, et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008;299:1277-1290.
  14. Chau DL, Edelman SV, Chandran M. Osteoporosis and diabetes. Curr Diab Rep. 2003;3:37-42.
  15. Hamilton EJ, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med. 2009;26:45-52.
  16. Forsén L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia. 1999;42:920-925.
  17. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32-38.
  18. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-1197.
  19. Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001;24:1198-1203.
  20. Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45:902-906.
  21. Kern LM, Powe NR, Levine MA, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med. 2005;142:173-181.
  22. Lentle B, Worsley D. Osteoporosis redux. J Nucl Med. 2006;47:1945-1959.
  23. Cummings SR. Bone density screening: A new level of evidence? Ann Intern Med. 2005;142:217-219.
  24. Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother. 2006;40:38-44.
  25. Nayak S, Olkin I, Liu H, et al. Meta-analysis: Accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144:832-841.
  26. International Osteoporosis Foundation. FRAX Identifying people at high risk of fracture.
  27. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473-477.
  28. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res. 2008;23:1061-1067.
  29. Cohen K, Maier D. Osteoporosis: Evaluation of screening patterns in a primary-care group practice. J Clin Densitom. 2008;11:498-502.
  30. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81:662-672.
  31. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163:2165-2172.
  32. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006;26:194-206.
  33. Gourlay M. Osteoporosis screening: mixed messages in primary care. Am Fam Physician. 2009;79:189-190.
  34. Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. Osteoporos Int. 2008;19:1505-1509.
  35. Newman ED, Ayoub WT, Starkey RH, et al. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14:146-151.

All electronic documents accessed September 15, 2010.


HOW TO TAKE THE POST-TEST: To obtain CME/CE credit, please click here after reading the article to take the post-test on myCME.com.